Should I buy or sell Fortrea stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortrea in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FTRE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FTRE, but not buy additional shares or sell existing shares. View FTRE analyst ratings or view top-rated stocks .

What is Fortrea's stock price target for 2024?

4 brokerages have issued 1-year price targets for Fortrea's shares. Their FTRE share price targets range from $27.00 to $38.00. On average, they predict the company's share price to reach $33.25 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price. View analysts price targets for FTRE or view top-rated stocks among Wall Street analysts .

How have FTRE shares performed in 2023?

Fortrea's stock was trading at $32.52 at the beginning of 2023. Since then, FTRE stock has decreased by 4.9% and is now trading at $30.94. View the best growth stocks for 2023 here .

When is Fortrea's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our FTRE earnings forecast .

How were Fortrea's earnings last quarter?

Fortrea Holdings Inc. (NASDAQ:FTRE) issued its quarterly earnings results on Monday, November, 13th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.08. The firm earned $776.40 million during the quarter, compared to analyst estimates of $748.90 million. The company's quarterly revenue was up 1.8% compared to the same quarter last year.

What ETFs hold Fortrea's stock?

ETFs with the largest weight of Fortrea (NASDAQ:FTRE) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD) , Invesco S&P SmallCap Health Care ETF (PSCH) , iShares Factors US Value Style ETF (STLV) , ETFMG Treatments Testing and Advancements ETF (GERM) , SPDR S&P 600 Small CapValue ETF (SLYV) , Global X Telemedicine & Digital Health ETF (EDOC) , iShares U.S. Healthcare Providers ETF (IHF) and iShares S&P Small-Cap 600 Value ETF (IJS) .

How do I buy shares of Fortrea?

Shares of FTRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Fortrea Stock Price, News & Analysis (NASDAQ:FTRE)

$30.94

-0.70 (-2.21%)

(As of 12/5/2023 ET)

Compare

Today's Range: $30.70
▼
$31.46
50-Day Range: $27.12
▼
$33.55
52-Week Range: $24.92
▼
$37.30

Volume: 531,961 shs
Average Volume: 1.73 million shs
Market Capitalization: $2.75 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.25

About Fortrea Stock (NASDAQ:FTRE)

Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. It offers phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. is based in Durham, North Carolina.

FTRE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FTRE Stock News Headlines

December 3, 2023 | americanbankingnews.com

Evercore ISI Upgrades Fortrea (NASDAQ:FTRE) to Outperform

December 3, 2023 | americanbankingnews.com

Fortrea (NASDAQ:FTRE) Shares Gap Up to $29.44

December 6, 2023 | Edge On The Street (Ad)

Energy Storage Trend Ignites Frenzy Over Vanadium Supply

As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.

December 1, 2023 | realmoney.thestreet.com

Fortrea Holdings upgraded to Outperform from In Line at Evercore ISI

December 1, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Fortrea Holdings

November 28, 2023 | markets.businessinsider.com

Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?

November 14, 2023 | msn.com

Fortrea upgraded at Barclays after Q3 beat

November 14, 2023 | seekingalpha.com

Fortrea Holdings Q3 Earnings: A Very Mixed Bag

December 6, 2023 | Edge On The Street (Ad)

Energy Storage Trend Ignites Frenzy Over Vanadium Supply

November 13, 2023 | finance.yahoo.com

Fortrea Holdings Inc (FTRE) Reports Mixed Q3 Results Amidst Transformation

November 13, 2023 | finanznachrichten.de

Fortrea Holdings Inc: Fortrea Reports Third Quarter 2023 Results

November 13, 2023 | finance.yahoo.com

Fortrea Reports Third Quarter 2023 Results

November 2, 2023 | finance.yahoo.com

Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

November 1, 2023 | morningstar.com

Fortrea Holdings Inc FTRE

October 27, 2023 | finance.yahoo.com

The recent drop in prices must have disappointed Fortrea Holdings Inc. (NASDAQ:FTRE) institutional investors who own 46% of the shares

October 18, 2023 | finance.yahoo.com

Here’s Why Madison Mid Cap Fund Elected to Sell Fortrea Holdings (FTRE)

October 17, 2023 | benzinga.com

Why Fortrea Holdings Shares Are Gaining Today

October 17, 2023 | wsj.com

Stocks to Watch Tuesday: Fortrea, Ericsson, J&J, Goldman Sachs

October 17, 2023 | au.investing.com

Fortrea gains as activist Starboard said to have built 5%+ stake

October 17, 2023 | msn.com

Activist Starboard takes more than 5% stake in Fortrea Holdings - WSJ

October 17, 2023 | msn.com

Fortrea Stock (NASDAQ:FTRE): Activist Investor Starboard Snaps Up Over 5% Stake

October 13, 2023 | finance.yahoo.com

Fortrea Appoints Life Science Executive Dr. John Doyle to Lead Consulting Team

October 11, 2023 | finance.yahoo.com

Fortrea Announces Date for Third Quarter 2023 Financial Results and Conference Call

October 11, 2023 | finance.yahoo.com

Fortrea Announces Date for Third Quarter 2023 Financial Results and Conference Call

October 10, 2023 | finance.yahoo.com

Fortrea’s Jim Cameli Named a Top 100 Global Chief Information Security Officer by HotTopics

October 6, 2023 | finance.yahoo.com

Here’s Why Vltava Fund Sold Fortrea Holdings (FTRE)

September 16, 2023 | finance.yahoo.com

Based On Its ROE, Is Fortrea Holdings Inc. (NASDAQ:FTRE) A High Quality Stock?

See More Headlines

Receive FTRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortrea and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FTRE
CUSIP: N/A
CIK: 1965040
Web: www.fortrea.com
Phone: 877-495-0816
Fax: N/A
Employees: 19,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.25
High Stock Price Target: $38.00
Low Stock Price Target: $27.00
Potential Upside/Downside: +7.5%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.93
Current Ratio: 1.62
Quick Ratio: 1.62

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 88,800,000
Free Float: N/A
Market Cap: $2.75 billion
Optionable: Not Optionable
Beta: N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Ms. Jill McConnell (Age 49)
Chief Financial Officer
Comp: $615.13k
Mr. Mark A. Morais (Age 47)
COO & President of Clinical Services
Comp: $537.45k
Mr. Thomas H. Pike (Age 64)
CEO, President & Chairman
Ms. Hima B. Inguva
Head of Investor Relations & Corporate Development
Dr. John J. Doyle
President of Consulting

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

FTRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Fortrea stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortrea in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FTRE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FTRE, but not buy additional shares or sell existing shares.
View FTRE analyst ratings or view top-rated stocks.
What is Fortrea's stock price target for 2024?: 4 brokerages have issued 1-year price targets for Fortrea's shares. Their FTRE share price targets range from $27.00 to $38.00. On average, they predict the company's share price to reach $33.25 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts price targets for FTRE or view top-rated stocks among Wall Street analysts.
How have FTRE shares performed in 2023?: Fortrea's stock was trading at $32.52 at the beginning of 2023. Since then, FTRE stock has decreased by 4.9% and is now trading at $30.94.
View the best growth stocks for 2023 here.
When is Fortrea's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our FTRE earnings forecast.

How were Fortrea's earnings last quarter?: Fortrea Holdings Inc. (NASDAQ:FTRE) issued its quarterly earnings results on Monday, November, 13th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.08. The firm earned $776.40 million during the quarter, compared to analyst estimates of $748.90 million. The company's quarterly revenue was up 1.8% compared to the same quarter last year.
What ETFs hold Fortrea's stock?: ETFs with the largest weight of Fortrea (NASDAQ:FTRE) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD), Invesco S&P SmallCap Health Care ETF (PSCH), iShares Factors US Value Style ETF (STLV), ETFMG Treatments Testing and Advancements ETF (GERM), SPDR S&P 600 Small CapValue ETF (SLYV), Global X Telemedicine & Digital Health ETF (EDOC), iShares U.S. Healthcare Providers ETF (IHF) and iShares S&P Small-Cap 600 Value ETF (IJS).
How do I buy shares of Fortrea?: Shares of FTRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:FTRE) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial